Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.97 USD | -5.29% | -10.45% | -48.56% |
05-02 | Acurx Pharmaceuticals, Inc. Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global Scientific Conference | CI |
04-04 | Top Premarket Gainers | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-48.56% | 31.17M | |
+21.74% | 46.4B | |
-0.97% | 41.75B | |
+49.39% | 41.37B | |
-3.52% | 29.71B | |
+11.12% | 26.01B | |
-19.37% | 19.52B | |
+31.18% | 12.43B | |
-0.04% | 12.13B | |
+0.39% | 12.18B |
- Stock Market
- Equities
- ACXP Stock
- News Acurx Pharmaceuticals, Inc.
- Transcript : Acurx Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 14, 2023